The latest price target for Ionis Pharmaceuticals (NASDAQ:IONS) was reported by Barclays on March 26, 2026. The analyst firm set a price target for $106.00 expecting IONS to rise to within 12 months (a possible 41.73% upside). 62 analyst firms have reported ratings in the last year.

The latest analyst rating for Ionis Pharmaceuticals (NASDAQ:IONS) was provided by Barclays, and Ionis Pharmaceuticals maintained their overweight rating.

The last upgrade for Ionis Pharmaceuticals Inc happened on October 8, 2025 when JP Morgan raised their price target to $80. JP Morgan previously had a neutral for Ionis Pharmaceuticals Inc.

The last downgrade for Ionis Pharmaceuticals Inc happened on August 2, 2024 when BMO Capital changed their price target from $67 to $60 for Ionis Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ionis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ionis Pharmaceuticals was filed on March 26, 2026 so you should expect the next rating to be made available sometime around March 26, 2027.

While ratings are subjective and will change, the latest Ionis Pharmaceuticals (IONS) rating was a maintained with a price target of $95.00 to $106.00. The current price Ionis Pharmaceuticals (IONS) is trading at is $74.79, which is out of the analyst’s predicted range.